OrbiMed’s Traws Pharma TRAW Stock Holding History

OrbiMed’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	1,203,260 +597,729	+99%	+$824K	0.02%	129
2026 Q1	$1.11M	Hold	605,531	–	–	0.02%	112
2025 Q4	$684K	Hold	605,531	–	–	0.01%	106
2025 Q3	$1.12M	Hold	605,531	–	–	0.03%	102
2025 Q2	$896K	Hold	605,531	–	–	0.02%	93
2025 Q1	$1.39M	Hold	605,531	–	–	0.03%	97
2024 Q4	$5.38M	Hold	605,531	–	–	0.11%	84
2024 Q3	$3.56M	Buy	605,531 +563,721	+1,348%	+$5.13M	0.06%	103
2024 Q2	$467K	Buy	+41,810	New	+$674K	0.01%	112

Other funds holding TRAW

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

OrbiMed's TRAW Position: Q2 2026 in Review

OrbiMed increased its Traws Pharma (TRAW) stake by 99% in Q2 2026, buying an estimated $824K and bringing the position to 1,203,260 shares worth $1.01M. The position accounts for 0.02% of the portfolio, ranked #129.

OrbiMed first reported a position in TRAW in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.38M in Q4 2024. 34 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

OrbiMed held 1,203,260 shares of Traws Pharma worth $1.01M as of Q2 2026.
OrbiMed bought 597,729 Traws Pharma shares in Q2 2026, an estimated $824K.
Traws Pharma made up 0.02% of OrbiMed's portfolio in Q2 2026, its #129 holding.
OrbiMed first reported a position in Traws Pharma in Q2 2024 and has held it in 9 quarters since.
OrbiMed's Traws Pharma position peaked at $5.38M in Q4 2024.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.